MoonLake ImmunotherapeuticsvsMerck & Company

MLTX and MRK stock compared: price, dividend, valuation and results, from SEC filings.

MLTX

MoonLake Immunotherapeutics

$11.07

Value $942M

+0.36%
MLTX's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

MoonLake Immunotherapeutics (MLTX) has a market value of $942M and Merck & Company (MRK) $331B. Over the last year, with dividends, MLTX moved -18.2% and MRK +44.8%. Dividend yield: MLTX none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MLTX$942M

    MRK$331B

    MRK is 351 times MLTX

  • Revenue, 12 months

    MLTX–

    MRK$67.4B

  • Net income, 12 months

    MLTX-$273M

    MRK$2.5B

  • Operating margin

    MLTX–

    MRK–

  • ROIC

    MLTX-51.1%

    MRK3.9%

    55.0 points apart

  • P/E

    MLTX–

    MRK134.8

  • Dividend yield

    MLTX0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    MLTX+11.6%

    MRK+93.0%

    81.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MLTX+11.6%

MRK+93.0%

20040060020222023202420252026
Returns by period
PeriodMLTXWith dividendsMRKWith dividends
1 year since November 19, 2025-18.2%Price -18.2%+44.8%Price +40.7%
3 years since November 20, 2023-74.1%-36.2% a yearPrice -74.1%+42.7%+12.6% a yearPrice +30.2%
5 years since November 19, 2021+11.6%+2.2% a yearPrice +11.6%+93.0%+14.1% a yearPrice +65.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MLTXMoonLake ImmunotherapeuticsMRKMerck & Company

Valuation

MLTXMRK
Valuation
Price$11.07$133.72
Market value$942M$331B
Enterprise value (EV)$544M$375B
P/E–134.8
P/E, 5-year median–14.8
P/B2.57.4
EV/EBIT–78.7
Free cash flow yield–4.5%

Results and growth

MLTXMRK
Results and growth
Revenue, 12 months–$67.4B
Net income, 12 months-$273M$2.5B
Free cash flow, 12 months-$244M$14.7B
Earnings per share, 12 months-$3.67$0.98
Revenue growth, year on year–1.3%
Revenue growth a year, past–+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

MLTXMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin––
Net margin–3.6%
ROIC-51.1%3.9%
ROE-82.5%5.2%

Balance sheet

MLTXMRK
Balance sheet
Cash$499M$9.7B
Total debt$102M$53.8B
Net debt / EBITDA–5.7
Interest cover-25.6×2.4×

Dividends and buybacks

MLTXMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MLTX or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, MoonLake Immunotherapeutics or Merck & Company?

By market value, Merck & Company ($331B) is about 350.9 times MoonLake Immunotherapeutics ($942M), at today's prices.

How did MLTX and MRK stock do over the last 5 years?

Since November 19, 2021, MLTX's price moved +11.6% and MRK's +65.7%. With dividends: MLTX +11.6% (+2.2% a year), MRK +93.0% (+14.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, MLTX or MRK?

The dividend yield at today's price is none for MoonLake Immunotherapeutics and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which is the better investment, MoonLake Immunotherapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.